Loading...
XOSLAKBM
Market cap496mUSD
Dec 20, Last price  
65.70NOK
1D
-0.45%
1Q
27.82%
IPO
-34.30%
Name

Aker Biomarine ASA

Chart & Performance

D1W1MN
XOSL:AKBM chart
P/E
—
P/S
1.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.89%
Rev. gr., 5y
16.81%
Revenues
335m
+20.96%
74,053,65612,189,59525,021,78652,050,55355,287,49484,002,607108,993,261112,299,000105,121,000116,737,000125,540,000154,182,000246,170,000288,588,000262,062,000277,200,000335,300,000
Net income
-9m
L
00028,916,9740046,593,795-17,258,000805,000-2,055,000-17,768,000-1,022,000-23,750,000-5,463,000-8,008,00010,000,000-9,000,000
CFO
47m
+213.91%
00002,513,0675,373,3010-11,134,00018,269,00020,880,00007,894,00012,307,000-51,043,000729,00015,100,00047,400,000
Dividend
Sep 09, 202445 NOK/sh
Earnings
Feb 12, 2025

Profile

Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.
URL
https://www.akerbiomarine.com/
IPO date
Jul 06, 2020
Employees
626
Domiciled in
NO
Incorporated in
NO

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
335,300
20.96%
277,200
5.78%
262,062
-9.19%
Cost of revenue
313,190
248,900
259,707
Unusual Expense (Income)
NOPBT
22,110
28,300
2,355
NOPBT Margin
6.59%
10.21%
0.90%
Operating Taxes
(25,000)
2,200
604
Tax Rate
7.77%
25.65%
NOPAT
47,110
26,100
1,751
Net income
(9,000)
-190.00%
10,000
-224.88%
(8,008)
46.59%
Dividends
Dividend yield
Proceeds from repurchase of equity
200
19
BB yield
-0.01%
0.00%
Debt
Debt current
49,000
47,600
30,731
Long-term debt
353,700
344,200
306,016
Deferred revenue
100
168
Other long-term liabilities
3,700
(100)
10,639
Net debt
375,100
360,600
327,500
Cash flow
Cash from operating activities
47,400
15,100
729
CAPEX
(45,900)
(46,100)
(81,107)
Cash from investing activities
(48,900)
(56,400)
(79,210)
Cash from financing activities
6,700
52,500
78,935
FCF
46,310
(1,449)
(64,190)
Balance
Cash
27,500
21,000
9,147
Long term investments
100
10,200
100
Excess cash
10,835
17,340
Stockholders' equity
(163,600)
(118,500)
(128,536)
Invested Capital
926,900
878,500
834,556
ROIC
5.22%
3.05%
0.22%
ROCE
2.90%
3.70%
0.33%
EV
Common stock shares outstanding
87,661
90,000
87,586
Price
46.00
20.89%
38.05
-29.93%
54.30
-53.79%
Market cap
4,032,409
17.75%
3,424,500
-28.00%
4,755,924
-48.15%
EV
4,407,509
3,817,900
5,114,424
EBITDA
72,310
77,700
53,437
EV/EBITDA
60.95
49.14
95.71
Interest
33,400
20,300
13,678
Interest/NOPBT
151.06%
71.73%
580.81%